Sionna reprices CFO options, grants new RSUs
Sionna Therapeutics granted its CFO new options at $7.18 and over 94,000 RSUs, including performance-based awards, as part of an option repricing and equity compensation package.
Rhea-AI Filing Summary
Sionna Therapeutics, Inc. reported equity compensation changes for its CFO and CBO, Elena Ridloff. On September 17, 2026, she received a non-qualified stock option for 165,440 shares of common stock at an exercise price of $7.18 per share, reflecting an option repricing that replaced a prior option over the same number of shares with a $39.21 exercise price. She was also granted 47,269 time-based RSUs vesting on June 17, 2027 and 47,268 performance-based RSUs that vest upon achievement of a designated performance milestone, in each case subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Ridloff Elena
Role
CFO and CBO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) F3, F4, F5 | 165,440 | $0.00 | $0.00 |
| Disposition | Non-Qualified Stock Option (right to buy) F4, F5 | 165,440 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 47,269 | $0.00 | $0.00 |
| Grant/Award | Common Stock F2 | 47,268 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 165,440 contracts (Direct);
Common Stock — 133,069 shares (Direct)
Footnotes (5)
- F1. Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest on June 17, 2027, subject to the Reporting Person's continued service with the Issuer as of the vesting date.
- F2. Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest upon the achievement of a designated performance milestone, subject to the Reporting Person's continued service with the Issuer as of the vesting date.
- F3. The exercise price of the option is $7.18 per share, representing the fair market value per share of the Issuer's Common Stock on September 17, 2026 (the "Repricing Date"). Unless otherwise provided by the Issuer's board of directors or its compensation committee, if the option is exercised before the applicable retention period ends, the exercise price will revert to its original exercise price. The retention period begins on the Repricing Date and ends on the earliest of (i) the 18-month anniversary of the Repricing Date (March 17, 2028), (ii) a Sale Event (as defined in the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the "2025 Plan")) or (iii) certain qualifying terminations of service.
- F4. Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- F5. This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Key Figures
New option shares: 165,440 shares
New option exercise price: $7.18 per share
Original option exercise price: $39.21 per share
+4 more
7 metrics
New option shares
165,440 shares
Non-qualified stock option grant on September 17, 2026
New option exercise price
$7.18 per share
Exercise price set at fair market value on September 17, 2026
Original option exercise price
$39.21 per share
Exercise price of option disposed to issuer in repricing
Time-based RSUs granted
47,269 units
RSUs vesting on June 17, 2027, subject to continued service
Performance-based RSUs granted
47,268 units
RSUs vesting upon achievement of a performance milestone
Retention period end date (latest)
March 17, 2028
18-month anniversary of the September 17, 2026 repricing date
Option expiration date
January 1, 2036
Expiration date for the reported stock options
Key Terms
restricted stock units ("RSUs"), option repricing, Sale Event, Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan, +2 more
6 terms
restricted stock units ("RSUs") financial
"Represents a grant of restricted stock units ("RSUs"). Each RSU repres"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
option repricing financial
"Effective on the Repricing Date, the Issuer's board of directors approv"
Sale Event financial
"ends on the earliest of (i) the 18-month anniversary ... (ii) a Sale Eve"
Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan financial
"as defined in the Sionna Therapeutics, Inc. 2025 Stock Option and Ince"
Rule 16b-6(d) regulatory
"Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3"
Rule 16b-3 regulatory
"Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What new stock options did Sionna Therapeutics (SION) grant to its CFO?
The CFO received a non-qualified stock option for 165,440 shares of Sionna Therapeutics common stock with an exercise price of $7.18 per share, representing the fair market value on September 17, 2026, subject to the existing vesting schedule.
What prior option was replaced in the SION Form 4 filing?
An existing stock option covering 165,440 shares with an exercise price of $39.21 per share was disposed of to the issuer as part of an option repricing effective September 17, 2026, with other terms remaining unchanged.
What time-based RSUs were granted to the CFO of Sionna Therapeutics (SION)?
The CFO was granted 47,269 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest on June 17, 2027, subject to her continued service with Sionna Therapeutics through the vesting date.
What performance-based RSUs were disclosed for SION’s CFO?
The CFO received 47,268 performance-based RSUs, each representing one share of common stock. These RSUs vest upon achievement of a designated performance milestone, subject to her continued service with the company at the vesting date.
Was a Rule 10b5-1 trading plan involved in the SION Form 4 transactions?
No. The filing indicates the Rule 10b5-1 checkbox is not marked, and the transactions are described as an option repricing and equity grants under the company’s 2025 Stock Option and Incentive Plan.
Under which plan were the new SION options issued to the CFO?
The new stock option reported for the CFO was issued under the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan, and it becomes exercisable according to the vesting schedule specified in the award agreement and previously reported disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
